Sulindac Antibodies

Target Information

Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has demonstrated significant anticancer activity, particularly through its active metabolite, sulindac sulfide. Structurally, sulindac is an indene derivative, and its analogs have been synthesized to enhance its therapeutic profile. These analogs include amide derivatives and nitric oxide-donating compounds, which have been evaluated for their antitumor activity across various cancer cell lines, including prostate, colon, and breast cancer. Sulindac sulfide acts as a gamma-secretase modulator, offering potential benefits in triple-negative breast cancer models without immune suppression. The drug's mechanism involves COX inhibition, although some analogs are designed to reduce COX-related inhibition while maintaining antitumor efficacy. Sulindac's gene location and specific molecular interactions are subjects of ongoing research, focusing on its binding modes with COX-1 and COX-2 enzymes.